Our untested hypothesis is that the improvement in vasoconstriction is linked to a balanced activity of NOS isoforms and a reduction in oxidative stress such as demonstrated in a model of pulmonary hypertension treated with a β3-AR agonist [33]. Here, ADRB3 is linked to pulmonary hypertension.